Thank you for your feedback!

• Antibody-Drug Conjugate (ADC) Service: Introduced services for targeted therapeutics. 

• Faster Transient Production: Reduced production times by automation and technological improvements. 

• Mass Spectrometry: Added advanced mass-spectrometry capabilities from protein intact mass to peptide mapping analysis to support activities from purification in-process decisions to forced degradation studies. 

• Nanobody Library: Launched a new alpaca naive nanobody library for antibody discovery. 

• Stability Studies: Added stability studies to provide comprehensive data on the shelf-life and reliability of biologics, ensuring that our clients receive consistent and well-characterized products throughout their lifecycle. 

• Chemiluminescence Immunoassay (CLIA): Developed a CLIA tailored for validating diagnostic antibodies, enhancing the accuracy and reliability of antibody diagnostics. 

On top of that, our brand new GMP facility with 50, 200, and 1000 L single-use bioreactors is taking shape, and we are preparing for regulatory certification in early 2025.